Asia-Pacific’s medical devices industry saw a drop of 25.58% in deal activity during April 2022, when compared with the last 12-month average, led by Winner Medical Group’s $114.35m acquisition of 55% stake in Zhejiang Longtai Medical Technology, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 32 medical devices industry deals worth $382m were announced for the region in April 2022, against the 12-month average of 43 deals.
Of all the deal types, venture financing saw most activity in April 2022 with 28 transactions, representing an 87.5% share for the region.
In second place was M&A with four deals capturing a 12.5% share of the overall deal activity for the month.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn terms of value of deals, M&A was the leading category in Asia-Pacific’s medical devices industry with $193.19m, followed by venture financing deals totalled $188.77m.
Asia-Pacific medical devices industry deals in April 2022: Top deals
The top five medical devices deals accounted for 76.02% of the overall value during April 2022.
The combined value of the top five medical devices deals stood at $290.35m, against the overall value of $382m recorded for the month.
The top five medical devices industry deals of April 2022 tracked by GlobalData were:
1) Winner Medical Group $114.35m acquisition deal for 55% stake in Zhejiang Longtai Medical Technology
2) The $74.59m acquisition of ResApp Health by Pfizer Australia Holdings
3) Globis Capital Partners &,Incubate Fund,SoftBank Vision Fund 2 and World Innovation Lab (WiL fund) $70m venture financing deal with AI Medical Service
4) The $15.71m venture financing of Shanghai Yipu Biotechnology by Industrial Capital
5) Boyuan Capital,Guotai Junan Innovation Investment and Yinshengtai Capital $15.7m venture financing deal with Shanghai Ruijing Biotechnology
